menu
    • menu
    [{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Loxicodegol","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nektar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nektar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Loxicodegol","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nektar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nektar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Loxicodegol","moa":"Mu opioid receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nektar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Loxicodegol","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nektar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nektar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Loxicodegol","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nektar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nektar Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Loxicodegol

    Menu

    Loxicodegol

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nektar Therapeutics

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Nektar Therapeutics

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Loxicodegol

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol

                            Details : The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee does not recommend NDA approval of Nektar's oxycodegol.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 14, 2020

                            Lead Product(s) : Loxicodegol

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nektar Therapeutics

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Nektar Therapeutics

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Loxicodegol

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dep...

                            Details : NKTR-181 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Chronic Pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 14, 2019

                            Lead Product(s) : Loxicodegol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nektar Therapeutics

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Nektar Therapeutics

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Loxicodegol

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Canc...

                            Details : NKTR-181 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Low Back Pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 20, 2015

                            Lead Product(s) : Loxicodegol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Nektar Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Nektar Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Loxicodegol

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain

                            Details : NKTR-181 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Low Back Pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 13, 2015

                            Lead Product(s) : Loxicodegol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Nektar Therapeutics

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Nektar Therapeutics

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Loxicodegol

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee ...

                            Details : NKTR-181 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 14, 2012

                            Lead Product(s) : Loxicodegol

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth